Stocks Industrials BNGO
NASDAQ · IndustrialsBionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. brought in $30.2M of revenue over the twelve months to June 30, 2026, up 10.0% from a year earlier. It posted a net loss of $32.2M. At June 30, 2026 it held $3.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Bionano Genomics, Inc.
- Net worth
- Bionano Genomics, Inc. has a market value (market cap) of $13M at the latest share price, and shareholders' equity of $31.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $28.5M (-7.4% year on year), with a net loss of $26.4M. Over the 12 months to June 30, 2026: revenue $30.2M, net loss $32.2M.
- Cash flow
- In fiscal 2025 operations used $16.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Bionano Genomics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Bionano Genomics, Inc. does
Bionano Genomics, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NASDAQ under the ticker BNGO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $28.5M | -$26.4M | -$4.85 | n/a |
| 2024 | $30.8M | -$112M | -$88.13 | n/a |
| 2023 | $36.1M | -$232.5M | -$408.60 | n/a |
| 2022 | $27.8M | -$132.6M | -$274.80 | n/a |
| 2021 | $18M | -$72.4M | -$155.32 | n/a |
| 2020 | $8.5M | -$41.1M | -$232.98 | -$38.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BNGO ranks in Industrials
Latest SEC filings
What Bionano Genomics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 21% to $8.2M versus the same quarter last year; diluted EPS -$0.64 versus -$1.99.
- August 10, 2026
- June 24, 2026Other event 8-K
- June 5, 2026
- May 28, 2026Other event 8-K
- May 14, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 3.6% to $6.7M versus the same quarter last year; diluted EPS -$0.76 versus -$1.15.
- May 13, 2026
Insider trades
What the people running Bionano Genomics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $9.7K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 4, 2026 | Luderer AlbertInterim Chief Executive, Director | Boughtindirect | 4,000 | $4.8K |
| August 21, 2026 | Luderer AlbertInterim Chief Executive, Director | Boughtindirect | 4,000 | $4.9K |
| June 3, 2026 | Oldakowski MarkCHIEF OPERATING OFFICER | Shares withheld for tax | 27 | $35.1 |
| June 3, 2026 | Chaubey AlkaCHIEF MEDICAL OFFICER | Shares withheld for tax | 24 | $31.2 |
| June 3, 2026 | Dixon Jonathan V.GENERAL COUNSEL | Shares withheld for tax | 24 | $31.2 |
| June 3, 2026 | Adamchak MarkPrincipal Accounting Officer | Shares withheld for tax | 7 | $9.1 |
| February 17, 2026 | Holmlin R. ErikPRESIDENT AND CEO, Director | Shares withheld for tax | 51 | $56.1 |
| February 17, 2026 | Oldakowski MarkCHIEF OPERATING OFFICER | Shares withheld for tax | 20 | $22 |
Who owns BNGO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ayrton Capital LLC13G, passive with 2 related filers | 9.99% | November 13, 2025 |
| CVI Investments, Inc.13G, passive with 1 related filers | 9.9% | August 14, 2026 |
| Lind Global Fund III LP13G, passive with 2 related filers | 9.35% | February 17, 2026 |
| Lincoln Alternative Strategies LLC13G, passive | 5.42% | September 17, 2025 |
Largest institutional holders
Insiders
6 insiders reported holding 11,637 shares in total, about $12.8K at the last price.
| Holder | Shares |
|---|---|
| Luderer AlbertInterim Chief Executive, Director | 8,0008,000 held indirectly |
| Holmlin R. ErikPRESIDENT AND CEO, Director | 1,657 |
| Oldakowski MarkCHIEF OPERATING OFFICER | 868 |
| Chaubey AlkaCHIEF MEDICAL OFFICER | 620 |
| Adamchak MarkPrincipal Accounting Officer | 253 |
| Dixon Jonathan V.GENERAL COUNSEL | 239 |
Questions about BNGO
What does Bionano Genomics, Inc. do?
Bionano Genomics, Inc. is a company in the Industrials sector, listed on NASDAQ as BNGO. Its shares trade on NASDAQ under the ticker BNGO.
What is Bionano Genomics, Inc.'s net worth?
Bionano Genomics, Inc. has a market value (market cap) of $13M at the latest share price, and shareholders' equity of $31.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bionano Genomics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $32.2M on revenue of $30.2M.
How much revenue does Bionano Genomics, Inc. make?
Over the twelve months to June 30, 2026 Bionano Genomics, Inc. reported revenue of $30.2M. That is 10.0% more than a year earlier.
When did Bionano Genomics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 14, 2026.
When is Bionano Genomics, Inc.'s next earnings report?
Bionano Genomics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BNGO with
Follow BNGO
Get an email when Bionano Genomics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bionano Genomics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.